Illumina (NASDAQ:ILMN) had its target price boosted by Cowen from $315.00 to $400.00 in a report issued on Thursday, September 6th, The Fly reports. They currently have a positive rating on the life sciences company’s stock.

ILMN has been the topic of several other reports. Argus set a $372.00 price target on Illumina and gave the stock a buy rating in a research report on Friday, August 10th. Morgan Stanley boosted their price target on Illumina from $180.00 to $195.00 and gave the stock an underweight rating in a research report on Thursday, May 31st. Piper Jaffray Companies upped their target price on Illumina from $272.00 to $329.00 and gave the company an overweight rating in a research report on Tuesday, July 17th. Deutsche Bank upped their target price on Illumina from $280.00 to $330.00 and gave the company a buy rating in a research report on Tuesday, July 31st. Finally, Canaccord Genuity upped their target price on Illumina from $270.00 to $290.00 and gave the company a top pick rating in a research report on Tuesday, May 29th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $308.25.

Illumina stock traded down $2.79 during midday trading on Thursday, hitting $353.12. 551,245 shares of the company were exchanged, compared to its average volume of 838,354. The firm has a market capitalization of $51.42 billion, a PE ratio of 88.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.97. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. Illumina has a fifty-two week low of $196.00 and a fifty-two week high of $357.93.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping the consensus estimate of $1.11 by $0.32. The firm had revenue of $830.00 million for the quarter, compared to analyst estimates of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. Illumina’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 EPS. analysts forecast that Illumina will post 5.46 earnings per share for the current fiscal year.

In related news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction on Friday, August 10th. The stock was sold at an average price of $331.39, for a total transaction of $3,313,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Francis A. Desouza sold 2,100 shares of the company’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $276.14, for a total value of $579,894.00. Following the transaction, the chief executive officer now owns 83,282 shares of the company’s stock, valued at $22,997,491.48. The disclosure for this sale can be found here. Insiders sold a total of 45,837 shares of company stock valued at $14,939,513 over the last quarter. Company insiders own 0.54% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of ILMN. Federated Investors Inc. PA grew its stake in Illumina by 3,088.6% during the 1st quarter. Federated Investors Inc. PA now owns 492,287 shares of the life sciences company’s stock worth $116,387,000 after buying an additional 476,848 shares during the last quarter. Millennium Management LLC grew its stake in shares of Illumina by 219.8% in the second quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock worth $153,318,000 after purchasing an additional 377,283 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Illumina in the first quarter worth $61,394,000. Summit Trail Advisors LLC grew its stake in shares of Illumina by 21,172.1% in the first quarter. Summit Trail Advisors LLC now owns 194,852 shares of the life sciences company’s stock worth $195,000 after purchasing an additional 193,936 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in shares of Illumina by 4.5% in the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after purchasing an additional 185,745 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Book Value Per Share in Stock Trading

The Fly

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.